Tumor necrosis factor inhibitors may result in weight gain in Psoriasis patients

In a study published in the Journal of the American Academy of Dermatology, the use of tumor necrosis factor inhibitors was associated with an increase in body weight and body mass index. Consideration for other treatments should be considered for patients who are overweight or obese.

Commonly used tumor necrosis factor inhibitors:

  • Adalimumab (Humira®)
  • Certolizumab pegol (Cimzia®)
  • Etanercept (Enbrel®)
  • Golimumab (Simponi®, Simponi Aria®)
  • Infliximab (Remicade®)